αII-Spectrin Breakdown Products (SBDPs): Diagnosis and Outcome in Severe Traumatic Brain Injury Patients
- 1 July 2010
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Neurotrauma
- Vol. 27 (7), 1203-1213
- https://doi.org/10.1089/neu.2010.1278
Abstract
In this study we assessed the clinical utility of quantitative assessments of αII-spectrin breakdown products (SBDP145 produced by calpain, and SBDP120 produced by caspase-3) in cerebrospinal fluid (CSF) as markers of brain damage and outcome after severe traumatic brain injury (TBI). We analyzed 40 adult patients with severe TBI (Glasgow Coma Scale [GCS] score ≤8) who underwent ventriculostomy. Patients requiring CSF drainage for other medical reasons served as controls. CSF samples were taken at admission and every 6 h thereafter for a maximum of 7 days and assessed using novel quantitative fragment-specific ELISAs for SBDPs. Outcome was assessed using the 3-month Glasgow Outcome Scale. Mean CSF levels of SBDPs were significantly higher in TBI patients than in controls at all time points examined. Different temporal release patterns of CSF SBDP145 and SBDP120 were observed. SBDP145 provided accurate diagnoses at all time points examined, while SBDP120 release was more accurate 24 h after injury. Within 24 h after injury, SBDP145 CSF concentrations significantly correlated with GCS scores, while SBDP120 levels correlated with age. SBDP levels were significantly higher in patients who died than in those who survived. SBDP145 levels (>6 ng/mL) and SBDP120 levels (>17.55 ng/mL) strongly predicted death (odds ratio 5.9 for SBDP145, and 18.34 for SBDP120). The time course of SBDPs in nonsurvivors also differed from that of survivors. These results suggest that CSF SBDP levels can predict injury severity and mortality after severe TBI, and can be useful complements to clinical assessment.Keywords
This publication has 84 references indexed in Scilit:
- Ubiquitin C-terminal hydrolase is a novel biomarker in humans for severe traumatic brain injury*Critical Care Medicine, 2010
- αII-Spectrin Breakdown Product Cerebrospinal Fluid Exposure Metrics Suggest Differences in Cellular Injury Mechanisms after Severe Traumatic Brain InjuryJournal of Neurotrauma, 2009
- Biochemical, Structural, and Biomarker Evidence for Calpain-Mediated Cytoskeletal Change After Diffuse Brain Injury Uncomplicated by ContusionJournal of Neuropathology and Experimental Neurology, 2009
- Better safe than sorry?BMJ, 2007
- Spectrin breakdown products in the cerebrospinal fluid in severe head injury – preliminary observationsActa Neurochirurgica, 2005
- Traumatic Brain Damage: Serum S-100 Protein Measurements Related to Neuroradiological FindingsJournal of Neurotrauma, 2000
- Simultaneous Degradation of αII- and βII-Spectrin by Caspase 3 (CPP32) in Apoptotic CellsPublished by Elsevier BV ,1998
- β-Amyloid precursor protein (βAPP) as a marker for axonal injury after head injuryNeuroscience Letters, 1993
- Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction.Stroke, 1991
- Brain spectrin(240/235) and brain spectrin(240/235E): two distinct spectrin subtypes with different locations within mammalian neural cells.The Journal of cell biology, 1986